- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04276636
Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency
Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency,a Prospective Cohort Study
Aims:Prospectively observe the effects of Caltrate supplementation on the chronic course of Crohn's disease patients, analyze whether the effect of Caltrate on CD patients is affected by factors such as disease site, disease activity, treatment, etc.Provide a certain theoretical basis for "precision treatment" for CD patients in the future.
Design:It is a prospective cohort study. Investigators include a total of 60 participants with CD according to the inclusion and exclusion criteria, and divide them into two groups to assess their initial disease activity and detect related indicators. At the same time,Investigators detect the Vitamin D Gene gene polymorphisms in all participants.One group is given Caltrate 0.6g per day orally, and the control group do not intervene. After 12 months, re-evaluate the disease activity and retest the relevant indicators, and use statistical methods to analyze whether Caltrate supplementation treatment can increase the serum 25 (OH) D level of CD participants, improve the condition of CD participants,relationship with Vitamin D Gene Polymorphism,and analyze the effect of Caltrate on participants with CD is affected by factors such as disease site, disease activity, and treatment.
Study Overview
Status
Intervention / Treatment
Detailed Description
- The research can be started only after approval by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University.
- According to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease" formulated by the Beijing Conference in 2018 as a standard, patients with clear diagnosis of CD are collected. Exclusion criteria included pregnancy, breastfeeding, liver and kidney dysfunction, concurrent autoimmune diseases, and use of antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes.
- Assess disease activity of CD participants based on the "Simplified Crohn's disease Activity Score".
- General information about participants with CD is collected.
- Detection of VDR gene polymorphisms using Snapshot technology.
- Serum C-reactive protein, erythrocyte sedimentation rate, white blood cells, albumin, creatinine, alanine aminotransferase, calcium and phosphorus levels are measured.
- The level of serum 25 (OH) D of participants is detected.
- Develop a treatment plan for participants.
- Participants are divided into two groups, one group is given oral Caltrate 0.6g / d, and the other group did not intervene.
- The above serum indicators are re-measured in the 12th month, and the condition of CD participants is also evaluated.
Follow-up for 12 months. By comparing the above indicators, observe that in the Han population:
- Can Caltrate supplementation increase serum 25 (OH) D levels in patients with CD?
- Can Caltrate supplementation improve the condition of patients with CD?
- whether vitamin D gene polymorphisms affect the efficacy of Caltrate supplementation therapy?
- Analyze whether the effect of Caltrate on CD patients is affected by factors such as disease site, disease activity, treatment, etc ..
- Through statistical analysis, comprehensive analysis of the effectiveness and safety of Caltrate supplementation in Han patients with CD, and its relationship with vitamin D gene polymorphisms, providing a theoretical basis for further "precise treatment" intervention in inflammatory bowel disease.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Xia sheng long, Master
- Phone Number: 0086-15868532956
- Email: xsl1989@foxmail.com
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- SAHWenzhouMU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clearly diagnosed patients with CD
- Vitamin D deficiency (<= 20ng / ml)
Exclusion Criteria:
- Pregnancy, lactation
- Liver and kidney insufficiency
- Co-morbid with other autoimmune diseases
- Use antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes
- Vitamin D level is normal or high
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Caltrate
This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
|
Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
|
No Intervention: Control
The other group do not interfere.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum 25 (OH) D level
Time Frame: 1year
|
Because serum 25 (OH) D levels are relatively stable, they are considered the most reliable indicator of vitamin D status.
|
1year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
White blood cell count
Time Frame: 1year
|
White blood cell count can be used to reflect the degree of inflammation in the body
|
1year
|
erythrocyte sedimentation rate
Time Frame: 1year
|
ESR can be used to reflect the degree of inflammation in the body.
|
1year
|
C-reactive protein.
Time Frame: 1year
|
C-reactive protein can be used to reflect the degree of inflammation in the human body
|
1year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xia Xia long, Master, Second Affiliated Hospital of Wenzhou Medical University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Nutrition Disorders
- Gastroenteritis
- Intestinal Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Inflammatory Bowel Diseases
- Vitamin D Deficiency
- Crohn Disease
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Antacids
- Calcium Carbonate
Other Study ID Numbers
- SAHoWMU-CR2020-01-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Deficiency
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
University Hospital, Clermont-FerrandTerminated
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthCompleted
-
Universidade de Passo FundoUnknownDeficiency, Vitamin DBrazil
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Wageningen UniversityDSM Nutritional Products, Inc.; Top Institute Food and NutritionCompletedElderly, Frail | Deficiency, Vitamin DNetherlands
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Okan UniversityArçelik A.Ş.Completed
-
Brigham and Women's HospitalCompletedVitamin d Deficiency
-
Bispebjerg HospitalCompletedObesity | Deficiency, Vitamin D
Clinical Trials on Caltrate Pill
-
Second Affiliated Hospital of Wenzhou Medical UniversityCompletedVitamin D Deficiency | Crohn Disease | Vitamin D SupplementChina
-
Shanghai Jiao Tong University School of MedicineMinistry of Science and Technology of the People´s Republic of ChinaUnknownColorectal AdenomaChina
-
University of Alabama at BirminghamCompletedObesity | Body Weight | Eating Behavior | HungerUnited States
-
Second Affiliated Hospital of Wenzhou Medical UniversityCompletedVitamin D Deficiency | Ulcerative Colitis | Vitamin D SupplementChina
-
Peking Union Medical College HospitalThe Second Hospital of Hebei Medical University; China-Japan Friendship Hospital and other collaboratorsUnknownAcute Ischemic StrokeChina
-
NYU Langone HealthCompleted
-
Guangzhou University of Traditional Chinese MedicineUnknownPost-stroke Patients With Motor and Sensory DysfunctionChina
-
Sprim ItaliaAlgaeCal Inc.Completed
-
Massachusetts General HospitalGaneden Biotech, Inc.TerminatedIrritable Bowel Syndrome | Major Depressive DisorderUnited States
-
Hvidovre University HospitalNot yet recruitingCirrhosis, Liver | Procedural Bleeding | Thrombocytopenia; Drugs